The injectable drug delivery market is technology driven and is marked by 'Threat of Obsolescence' wherein technologies as well as its adoption by patients changes very rapidly.
The industry has seen a shift in paradigm and is now skewed toward self-injection devices that not only cures serious illnesses, but also have fewer serious side effects. The market for injectable drug delivery includes devices and formulations. Traditionally, injectable devices were primarily designed for delivery of insulin and human growth hormones. However, due to technological advancements they are currently being used as combination therapies for the delivery of a wide variety of drug classes such as anticholinergic, hematopoietic, dopamine agonists, parathyroid hormones, reproductive hormones, serotonin antagonists, sympathomimetic and immune modulators.
Self injection devices including auto injectors and pen injectors are the fastest growing segments in the injectable drug delivery market. In recent years, the uptake and adoption of self-injection devices such as auto and pen injectors has grown substantially. This is due to the benefits it offers over conventional injection devices. Self-injection devices ensure better patient adherence to treatment due to decrease risk of missed injection or drug discontinuation, and reduced healthcare cost as costly hospital visits are curtailed. This has ignited the interest of device manufacturers who are in turn incessantly coming up with new variants of self-injection devices with advanced technological features.
Triggered by the upsurge of biologics and injectable drugs, pharmaceutical companies are increasingly adopting and venturing into self injection and microneedles injectable drug delivery technologies. These investments are likely to fortify global foot print of injectable manufacturers, helping them to extend their term of exclusivity for patented drugs with added therapeutic benefits, and to bring up new innovations in injectable devices segment. For instance, in February 2013, SHL Group expanded its auto injector facility in Taiwan with the investment of ~$40 million. The expansion increases the manufacturing capabilities of auto injectors for the firm. Similarly, in January 2012, Clearside Biomedical (an Atlanta-based start up) received $4 million from Hatteras Venture Partners (a venture capital firm in the U.S.) for the development of microinjection technology.
In the coming years, growth of injectable drug delivery market is likely to be hinged at China, India, Brazil, and Mexico. These countries offer an array of opportunities for growth and are likely to serve as revenue pockets for injectable drug delivery technologies market. All these countries offer high growth potential as compared to mature countries such as U.S. and Canada. Growth in these markets is spurred by the growing incidence of diabetes and cancer as the population ages. According to the International Diabetes Federation (IDF), diabetes affects ~285 million people globally, and this number is expected to reach 438 million by 2030, with two-thirds of all diabetes cases in low- to middle-income countries. In addition, British medical journal Lancet states that Asia's cancer rate is projected to reach the figure of 7.1 million new cases by 2020 (an increase of almost 60% compared to 2005). Thus, to meet the increasing demand of injectables for the treatment of chronic diseases in emerging markets, manufacturers are strategically focusing on new product launches, agreements and partnerships, resorting to geographical expansion to increase their market share. Regulatory policies in the Asia-Pacific region are more adaptive and business friendly due to less stringent regulations and less extensive data requirement. Increasing competition in mature markets will further trigger injectable drug delivery technologie